Shares of ABBISKO-B surged 5.83% during intraday trading on Wednesday, following a series of positive corporate announcements.

The movement appears to be driven by the company's announcement that its subsidiary has dosed the first patient in a Phase I/II clinical study for ABSK141, an oral, highly potent, and selective small-molecule KRAS G12D inhibitor targeting advanced solid tumors. The study had previously received Investigational New Drug approvals from both the U.S. FDA and China's NMPA in December 2025. KRAS G12D is a common oncogenic driver with no approved targeted therapy globally, making this a significant step in the drug's development pipeline.

Additionally, investor sentiment may have been bolstered by a separate filing indicating that the company's CEO purchased 45,000 shares in the open market the previous day, a move often interpreted as a signal of insider confidence in the firm's prospects.